Genentech's staying power

An exodus of employees from Genentech Inc. - widely assumed to be inevitable now that the biotech is fully owned by Roche - may turn out to be slower than expected as a result of some shrewd management decisions and the sluggish economy.

Details of the integration of commercial operations have not been disclosed, but on the research side the pharma looks to be making good on its promise to allow Genentech to operate independently, preserving important aspects of the biotech's culture of innovation...